Researchers’ Experiences with IRB Oversight of Psychedelic Research
Ethics & Human Research · 2026-11 · 48 (6) · 6-19
DOI: 10.1002/eahr.70033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ethics & Human Research, online erschienen am 06.11.2026. Verfasst von Logan Neitzke-Spruill und 5 weiteren Autor:innen. Beteiligte Einrichtung: Postdoctoral associate at the Center for Medical Ethics and Health Policy at Baylor College of Medicine. Hauptthemen laut MEDLINE: Ethics Committees, Research, Hallucinogens, Research Personnel, Biomedical Research. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Greenwall Foundation, Greenwall Foundation.
Abstract (Originalsprache)
Previous research raises concern that conservative institutional review board (IRB) approaches regarding stigmatized issues and vulnerable groups could similarly arise as an impediment to research with psychedelic drugs. We interviewed 20 US researchers who had been a principal investigator on at least one research protocol involving psychedelics about their experiences with IRB oversight and perspectives regarding what IRBs need to know. Respondents reported that their IRBs raised concern and asked questions about participant safety, consent, legal issues, and data security and confidentiality, typical domains for IRB consideration. They also mentioned several IRB knowledge gaps or misunderstandings about psychedelics, primarily about risks and safety, while emphasizing the importance of IRBs’ understanding of psychedelic drug effects. Despite IRB concerns and misunderstandings, all study respondents ultimately reported positive or neutral current experiences with IRBs reviewing their protocols for research with psychedelics, which they often attributed to cultivating strong IRB relationships and helping IRBs achieve adequate knowledge about these types of studies. Although investigators in our study did not perceive their IRBs to be a significant barrier to research with psychedelics, less experienced investigators and IRBs may face different outcomes. As research with psychedelics continues to increase, both researchers and IRBs should be responsive to continued scientific developments and emergent best practices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Postdoctoral associate at the Center for Medical Ethics and Health Policy at Baylor College of Medicine.
- Research manager at the Center for Medical Ethics and Health Policy at Baylor College of Medicine.
- Fourth-year medical student at McGovern Medical School at the University of Texas Health Science Center Houston.
- Associate professor of medical ethics at the Perelman School of Medicine at the University of Pennsylvania.
- Leon Jaworski Professor of Biomedical Ethics and director of the the Center for Medical Ethics and Health Policy at Baylor College of Medicine.
- Associate professor of medical ethics and law at the Perelman School of Medicine at the University of Pennsylvania.
Förderung
- The Greenwall Foundation
- Greenwall Foundation
Zitieren
APA
Neitzke-Spruill, L., Robinson, J. O., Purcell, A., Sisti, D., McGuire, A. L., & Lynch, H. F. (2026). Researchers’ Experiences with IRB Oversight of Psychedelic Research. Ethics & Human Research, 48(6), 6-19. https://doi.org/10.1002/eahr.70033
Vancouver
Neitzke-Spruill L, Robinson JO, Purcell A, Sisti D, McGuire AL, Lynch HF. Researchers’ Experiences with IRB Oversight of Psychedelic Research. Ethics & Human Research. 2026;48(6):6-19. doi:10.1002/eahr.70033
BibTeX
@article{NeitzkeSpruill2026,
author = {Neitzke-Spruill, Logan and Robinson, Jill Oliver and Purcell, Alison and Sisti, Dominic and McGuire, Amy L and Lynch, Holly Fernandez},
title = {Researchers’ Experiences with IRB Oversight of Psychedelic Research},
journal = {Ethics & Human Research},
year = {2026},
volume = {48},
number = {6},
pages = {6--19},
doi = {10.1002/eahr.70033}
}
EUVIMED